These drugs will attack cancer cells in the body without damaging surrounding healthy ones.

Our chief focus for future investments will be: One on increasing our R&D footprint here over time. Second is data and digital.

The U.S. Food and Drug Administration on Wednesday approved a radical new one-time treatment from the Swiss drugmaker, weeks earlier than e...